Literature DB >> 12037684

G-protein alpha(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells.

Karine Régnauld1, Quang-Dé Nguyen, Luc Vakaet, Erik Bruyneel, Jean-Marie Launay, Takeshi Endo, Marc Mareel, Christian Gespach, Shahin Emami.   

Abstract

The heterotrimeric G-protein subunits Galpha and Gbetagamma are involved in cellular transformation and tumor development. Here, we report the expression of Galpha(olf) in human digestive and urogenital epithelial cells using RT-PCR and Western blot. When the constitutively activated form of Galpha(olf)Q214L (AGalpha(olf)) was stably transfected in canine kidney MDCKts.src and human colonic HCT-8/S11 epithelial cells, it induced cellular invasion in collagen gels. AGalpha(olf)-mediated invasion was abrogated by agonists of platelet activating factor receptors (PAF-R) and protease-activated receptors -1 (PAR-1), pharmacological inhibitors of PI3'-Kinase (wortmannin), protein kinase C (Gö6976 and GF109203X), Rho GTPase (C3T exoenzyme), but was independent of protein kinase A. Accordingly, the invasive phenotype induced by AGalpha(olf) in HCT-8/S11 cells was reversed by the RhoA antagonist RhoD (G26V). Although AGalpha(olf) protected MDCKts.src cells against serum starvation-mediated apoptosis via a Rho-independent pathway, both AGalpha(olf) and Rho inhibition by C3T induced neuroendocrine-like differentiation linked to extensive neurite outgrowth and parathyroid hormone-related protein expression in human prostatic LNCaP-AGalpha(olf) cells. Since prostate tumors with a larger neuroendocrine cell population display increased invasiveness, persistent activation of the G-protein alpha(olf) may exert convergent adverse effects on cellular invasion and survival in solid tumors during the neoplastic progression towards metastasis. doi:10.1038/sj.onc.1205498

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037684     DOI: 10.1038/sj.onc.1205498

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment.

Authors:  Benoît Romain; Agnès Neuville; Nicolas Meyer; Cécile Brigand; Serge Rohr; Anne Schneider; Marie-Pierre Gaub; Dominique Guenot
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

2.  Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.

Authors:  Chun-Hui Yi; Tongzhang Zheng; Derek Leaderer; Aaron Hoffman; Yong Zhu
Journal:  Cancer Lett       Date:  2009-05-19       Impact factor: 8.679

3.  Evolution of class-specific peptides targeting a hot spot of the Galphas subunit.

Authors:  Ryan J Austin; William W Ja; Richard W Roberts
Journal:  J Mol Biol       Date:  2008-01-18       Impact factor: 5.469

4.  Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.

Authors:  Guenhaël Sanz; Isabelle Leray; Aurélie Dewaele; Julien Sobilo; Stéphanie Lerondel; Stéphan Bouet; Denise Grébert; Régine Monnerie; Edith Pajot-Augy; Lluis M Mir
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 5.  β-Adrenergic Receptor Signaling in Prostate Cancer.

Authors:  Peder Rustøen Braadland; Håkon Ramberg; Helene Hartvedt Grytli; Kristin Austlid Taskén
Journal:  Front Oncol       Date:  2015-01-12       Impact factor: 6.244

6.  Invasion and MMP expression profile in desmoid tumours.

Authors:  H Denys; O De Wever; B Nusgens; Y Kong; R Sciot; A-T Le; K Van Dam; A Jadidizadeh; S Tejpar; M Mareel; B Alman; J-J Cassiman
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

7.  Detection of genome-wide copy number variations in two chicken lines divergently selected for abdominal fat content.

Authors:  Hui Zhang; Zhi-Qiang Du; Jia-Qiang Dong; Hai-Xia Wang; Hong-Yan Shi; Ning Wang; Shou-Zhi Wang; Hui Li
Journal:  BMC Genomics       Date:  2014-06-24       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.